Azitra is trading at $1.32, down 13.73% in pre-market, with no confirmed company-specific news explaining the decline.
- Azitra reported positive ex vivo ATR-COSF results on October 26, but available coverage does not link them to the current move.
- The previously announced 1-for-10 reverse stock split took effect October 26; it is context, not an established reason for the decline.
- Market indicators are mixed, and supplied price history shows an unusually large prior-session jump.